Navigation Links
Trazodone in Medical News

Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET

LAVAL, QC, Dec. 15 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) will host a webcast presentation on, Tuesday, December 16, 2008, at 10:00 am (ET) during which the Company's senior management team will discuss the product profile, clinical and regulatory progress and the mark...

Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder

LAVAL, QC, Nov. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) today announced that it will host a webcast presentation on Tuesday, December 16, 2008 at 10:00 am (ET) during which the Company's senior management team will discuss the product profile, clinical and regulatory...

Labopharm's NDA for Novel Trazodone Formulation accepted for review by FDA

- Action Date is July 18, 2009 - LAVAL, QC, Nov. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) today announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SAR...

Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug

LAVAL, QC, Sept. 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has completed patient enrolment in its North American Phase III clinical trial for its once-daily formulation of the antidepressant trazodone (study 04ACL3-001). More than 400 patients ...

Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone

- Study Achieves Primary Efficacy Endpoint and Demonstrates Improved Quality of Sleep - LAVAL, QC, Feb. 8 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that its recently completed North American Phase III clinical trial for its onc...

Labopharm Reports Results for Second Quarter Fiscal 2009

...inue to prepare for commercialization of our novel trazodone formulation in the U.S.," concluded Mr. Howard-Tri..., the United Kingdom, Spain and Italy. Novel trazodone Formulation Company to Submit Response to FDA...e Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is...

Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference

... 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on...

Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)

... 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on...

Labopharm receives complete response letter from the U.S. FDA for novel antidepressant

... not been questioned about the continued supply of trazodone hydrochloride to the U.S. market. Angelini intends...arm submitted the NDA for its novel formulation of trazodone in September 2008. The NDA is based on data from f...e Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is...

Labopharm amends debt facility agreement with Hercules

...round the world, including the U.S., Canada, major European markets, and Australia, among others. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in...
Trazodone in Medical Technology

Labopharm files New Drug Submission with Health Canada for novel antidepressant

...sants represents a significant opportunity for our trazodone formulation and we are currently in discussions wi...score from baseline to the end of the study in the trazodone group versus the placebo group. Statistical signif...'s trazodone. In addition, patients on Labopharm's trazodone demonstrated significant improvements versus place...
Other Tags
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their flagship ... at the 2015 Vans US Open of Surfing, July 25 through August 2 in ... added sugar” on the market, is a natural choice given the Open’s commitment to ...
(Date:7/31/2015)... Los Angeles, CA (PRWEB) , ... July 31, 2015 , ... According to the ... the third floor of the Pasadena courthouse was contained and extinguished by the city’s fire ... one was in the building at the time of the fire, and it was a ...
(Date:7/31/2015)... New York (PRWEB) , ... ... ... trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now ... 28th, 2015 was well received with a 94% approval rating from the ...
(Date:7/31/2015)... ... 2015 , ... The 2015 New York Regional Conference on ... professionals, and researchers, covering a variety of topics related to mesothelioma and presented ... the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer Center. , The ...
(Date:7/31/2015)... MA (PRWEB) , ... July 31, 2015 , ... ... this year’s “HARMONY 2015”, one of the industry’s premier thought leadership symposiums, ... November 5 and 6. The event attracts over 250 “C”-level executives, administrators, ...
Breaking Medicine News(10 mins):Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3
(Date:7/21/2015)... 2015 Passwords have proven futile for ... recent U.S. Office of Personnel Management breach. Biometric ... conundrum, but developers and end-users are concerned about ... dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today the ... third party integration. A video ...
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
Other Contents